Areas of expertise

• Cancer Cell Biology 111201
• Cancer Genetics 111203
• Cancer Therapy (Excl. Chemotherapy And Radiation Therapy) 111204
• Haematological Tumours 111206
• Molecular Targets 111207
• Cell Development, Proliferation And Death 060103
• Signal Transduction 060111
• Biochemistry And Cell Biology 0601

Research interests

Biography

Publications

• Kusnadi, E, Trigos, A, Cullinane, C et al. 2020, 'Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis', The EMBO Journal, vol. 39, no. 21, pp. -.
• Hannan, K, Hannan, R, Yan, S et al. 2020, 'The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer', British Journal of Cancer, vol. 124, pp. 616-627.
• Son, J, Hannan, K, Poortinga, G et al. 2020, 'rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461', Frontiers in Cell and Developmental Biology, vol. 8, pp. 1-14.
• Zaytseva, O, Mitchell, N, Guo, L et al. 2020, 'Transcriptional repression of Myc underlies the tumour suppressor function of AGO1 in Drosophila', Development, vol. 147, no. 11, pp. -.
• Chin, C, Antony, J, Ketharnathan, S et al. 2020, 'Cohesin mutations are synthetic lethal with stimulation of WNT signaling', eLife, vol. 9.
• Sanij, E, Hannan, K, Xuan, J et al. 2020, 'CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer', Nature Communications, vol. 11, no. 1, pp. -.
• Thejer, B, Adhikary, P, Kaur, A et al. 2020, 'PGRMC1 phosphorylation affects cell shape, motility, glycolysis, mitochondrial form and function, and tumor growth', BMC Molecular and Cell Biology, vol. 21, no. 1, pp. -.
• Chan, K, Blake, S, Zhu, H et al. 2020, 'A functional genetic screen defines the AKT-induced senescence signaling network', Cell Death and Differentiation, vol. 27, pp. 725-741.
• Gao, J, Jung, M, Mayoh, C et al. 2020, 'Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression', Cancer Research, vol. 80, no. 17, pp. 3706-3718.
• Ferreira, R, Schneekloth Jr., J, Panov, K et al. 2020, 'Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age', Cells, vol. 9, no. 2.
• Franks, S, Firipis, K, Ferreira, R et al. 2020, 'Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents', Materials Horizons, vol. 7, no. 8, pp. 1996-2010.
• Wagner, S, Herrmannová, A, Hronová, V et al. 2020, 'Selective Translation Complex Profiling Reveals Staged Initiation and Co-translational Assembly of Initiation Factor Complexes', Molecular Cell, vol. 79, no. 4, pp. 546-560.
• Khot, A, Brajanovski, N, Cameron, D et al 2019, 'First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study', Cancer Discovery, vol. 9, no. 8, pp. 1036-1049.
• Diesch, J, Bywater, M, Sanij, E et al 2019, 'Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation', Communications Biology, vol. 2, no. 39, pp. 1-14pp.
• Somers, K, Wen, V, Middlemiss, S et al. 2019, 'A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction', Oncogene, vol. 38, no. 20, pp. 3824-3842.
• Liu, P, Tee, A, Milazzo, G et al. 2019, 'The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35', Nature Communications, vol. 10.
• Shirokikh, N, Dutikova, Y et al 2019, 'Migration of Small Ribosomal Subunits on the 5' Untranslated Regions of Capped Messenger RNA', International Journal of Molecular Sciences, vol. 20, no. 18. pp. 4464
• Shirokikh, N, Dutikova, Y et al 2019, 'Migration of Small Ribosomal Subunits on the 5' Untranslated Regions of Capped Messenger RNA', International Journal of Molecular Sciences, vol. 20, no. 18. pp. 4464
• Chen, J, Siva, K, Rzymski, T et al. 2018, 'Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs [Meeting Abstract]', Blood, vol. 132, no. 1.
• March, L, Willers, C, Ellis, J et al 2018, 'The Australian Arthritis and Autoimmune Biobank Collaborative (A3BC) Protocol', 2018 Australian Rheumatology Association Annual Scientific Meeting with the Rheumatology Health Professionals Association, ed. Jeff Szer, Wiley-Blackwell Publishing Asia, Australia, pp. 23-24.
• MacLachlan, K, Cuddihy, A, Hein, N et al 2018, 'Novel combination therapy targeting rDNA transcription and Histone Deacetylation Provides Effective Treatment for Multiple Myeloma, and Synergises in Bortezomib-Resistant MM', <>, p. 1945.
• Martin, C, Cullinane, C, Kirby, L et al 2018, 'Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance', International Journal of Cancer, vol. 142, no. 10, pp. 2139-2152.
• Udugama, M, Sanij, E, Voon, H et al 2018, 'Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers', PNAS - Proceedings of the National Academy of Sciences of the United States of America, vol. 115, no. 18, pp. 4737-4742pp.
• He, J, Soo, H, Evers, M et al. 2018, 'High-Content Imaging Approaches to Quantitate Stress-Induced Changes in Nucleolar Morphology', Assay and Drug Development Technologies, vol. 16, no. 6, pp. 320-332pp.
• Lawrence, M, Obinata, D, Sandhu, S et al 2018, 'Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy', European Urology, vol. 74, no. 5, pp. 562-572.
• Rebello, R, Kusnadi, E, Cameron, D et al 2017, 'Abstract B23: Inhibition of ribosomal RNA synthesis as a new therapeutic approach to treat advanced prostate cancer', Cancer Research, vol. 77, no. 6.
• Venugopal, P, Moore, S, Lawrence, D et al 2017, 'Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan Anemia patient', Haematologica, vol. 102, no. 12, pp. e506-e509pp.
• Hein, N, Hannan, K, D'Rozario, J et al. 2017, 'Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer', Technology in Cancer Research and Treatment, vol. 16, no. 6, pp. 736-739pp.
• Lefebure, M, Tothill, R, Kruse, E et al. 2017, 'Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene', Nature Communications, vol. 8, pp. 1-10pp.
• Kerry, L, Pegg, E, Cameron, D et al. 2017, 'Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis', PLoS Neglected Tropical Diseases, vol. 11, no. 3, pp. -.
• Rebello, R, Pearson, R, Hannan, R et al 2017, 'Therapeutic approaches targeting MYC-Driven prostate cancer', GENES, vol. 8, no. 2, pp. 16pp.
• Hein, N, Cameron, D, Hannan, K et al. 2017, 'Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population', Blood, vol. 129, no. 21, pp. 2882-2895pp.
• Yan, S, Chan, K, Simpson, K et al. 2017, 'Abstract A24: A genome-wide RNAi screen identifies synthetic lethality of CX-5461 with homologous recombination repair deficiency in ovarian cancer', Molecular Cancer Research, vol. 15, no. 4.
• Hannan, R, Hein, N, Hannan, K et al. 2017, 'Abstract IA10: Drugging the ribosome at the level of synthesis and translation to treat solid and hematologic cancers', Cancer Research, vol. 77, no. 6.
• Yan, S, Frank, D, Son, J et al. 2017, 'The potential of targeting ribosome biogenesis in high-grade serous ovarian cancer', International Journal of Molecular Sciences, vol. 18, no. 1, pp. -.
• Moily, N, Ormsby, A, Stojilovic, A et al 2017, 'Transcriptional profiles for distinct aggregation states of mutant Huntingtin exon 1 protein unmask new Huntington's disease pathways', Molecular and Cellular Neuroscience, vol. 83, pp. 103-112pp.
• Hung, S, Lesmana, A, Peck, A et al. 2017, 'Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription', Gene, vol. 612, pp. 36-48pp.
• Hung, S, Lesmana, A, Peck, A et al. 2017, 'Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription', Gene, vol. 612, pp. 36-48.
• Rebello, R, Kusnadi, E, Cameron, D et al 2016, 'The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer', Clinical Cancer Research, vol. 22, no. 22, pp. 5539-5552pp.
• Guo, L, Zaysteva, O, Nie, Z et al 2016, 'Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the Mediator Complex to modulate MYC transcription and tissue growth', Nucleic Acids Research, vol. 44, no. 16, pp. 7646-7658.
• Quin, J, Chan, K, Devlin, J et al. 2016, 'Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling', Oncotarget, vol. 7, no. 31, pp. 49800-49818.
• Kang, J, Kusnadi, E, Ogden, A et al. 2016, 'Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription', Oncotarget, vol. 7, no. 31, pp. 48887-48904.
• Chan, K, Paavolainen, L, Hannan, K et al. 2016, 'Combining high-content imaging and phenotypic classification analysis of senescence-associated beta-galactosidase staining to identify regulators of oncogene-induced senescence', Assay and Drug Development Technologies, vol. 14, no. 7, pp. 416-428.
• Colebatch, A, Di Stefano, L, Hannan, R et al 2016, 'Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies', Oncotarget, vol. 7, no. 41, pp. 66569-66585.
• Devlin, J, Hannan, K, Hein, N et al. 2016, 'Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma', Cancer Discovery, vol. 6, no. 1, pp. 59-70.
• Guo L., Zaysteva O., Nie Z, Mitchell N.C., Lee JEA. et al Hannan R.D., Levens D.L.,Quinn L.M. 2016, 'Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growth', Nucleic Acids Research, vol. 44, no. 16, pp. 7646-7658.
• Gilan, O, Diesch, J, Amalia, M et al 2015, 'PR55 alpha-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity', Oncogene, vol. 34, no. 10, pp. 1333-1339.
• Harrison, S, George, A & Hannan, R 2015, 'Commentary - A new window on cancer therapy? Targeting the nucleolus and ribosome biogenesis using the small molecule inhibitor of polymerase I transcription, CX-5461', International Journal of Hematologic Oncology, vol. 4, no. 2, pp. 61-65pp.
• Pereira, L, Mariadason, J, Hannan, R et al 2015, 'Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer', Frontiers in Oncology, vol. 5, no. 13, pp. -.
• Lee, J, Mitchell, N, Zaytseva, O et al. 2015, 'Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models', Nature Communications, vol. 6, pp. 7404-7404.
• Kusnadi, E, Hannan, K, Hicks, R et al. 2015, 'Regulation of rDNA transcription in response to growth factors, nutrients and energy', Gene, vol. 556, no. 1, pp. 27-34.
• Sanji, E, Diesch, J, Lesmana, A et al 2015, 'A novel role for the pol I transcription factor ubtf in maintaining genome stability through the regulation of highly transcribed pol II genes', Genome Research, vol. 25, no. 2, pp. 201-212.
• Diesch, J, Hannan, R & Sanij, E 2015, 'Genome wide mapping of UBF binding-sites in mouse and human cell lines', Genomics Data, vol. 3, pp. 103-105.
• Poortinga, G, Quinn, L & Hannan, R 2015, 'Targeting RNA polymerase I to treat MYC-driven cancer', Oncogene, vol. 34, no. 4, pp. 403-412.
• Woods, S, Hannan, K, Pearson, R et al. 2015, 'The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, vol. 1849, no. 7, pp. 821-829.
• Mitchell, N, Tchoubrieva, E, Chahal, A et al. 2015, 'S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila', Cellular Signalling, vol. 27, no. 10, pp. 2045-2053.
• Sjogren, S, Siva, K, Soneji, S et al 2015, 'Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia', British Journal of Haematology, vol. 171, no. 4, pp. 517-529.
• Lee, J, Mitchell, N, Zaytseva, O et al Levens D.L., Hannan R.D., and Quinn L.M. 2015, 'Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models', Nature Communications, vol. 6, no. 15, p. 7404.
• Mitchell, N, Tchoubrieva, E, Chahal, A et al Hannan R.D. and Quinn L.M. 2015, 'S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila', Cellular Signalling, vol. 27, no. 10, pp. 2045-2053.
• Quinn, L & Hannan, R 2015, 'MLK4 activates the NF-kB network to drive mesenchymal transition in glioblastoma', Translational Cancer Research, vol. 5, no. 6, pp. 6pp.
• Diesch, J, Hannan, R & Sanij, E 2014, 'Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease', Cell and Bioscience, vol. 4, no. 1, pp. 43 (11pp).
• Diesch, J, Sanij, E, Gilan, O et al 2014, 'Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells', PLOS ONE (Public Library of Science), vol. 9, no. 3, pp. e88950-e88950.
• Drygin, D, O'Brien, S, Hannan, R et al 2014, 'Targeting the Nucleolus for cancer-specific activation of p53', Drug Discovery Today, vol. 19, no. 3, pp. 259-265.
• Quin, J, Devlin, J, Cameron, D et al. 2014, 'Targeting the nucleolus for cancer intervention', Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1842, no. 6, pp. 802-816.
• Hamdane, N, Stefanovsky, V, Tremblay, M et al 2014, 'Conditional Inactivation of Upstream Binding Factor Reveals Its Epigenetic Functions and the Existence of a Somatic Nucleolar Precursor Body', PLoS Genetics, vol. 10, no. 8, pp. e1004505-e1004505.
• Foster, S, Porrello, E, Purdue, B et al 2013, 'Expression, Regulation and Putative Nutrient-Sensing Function of Taste GPCRs in the Heart', PLOS ONE (Public Library of Science), vol. 8, no. 5, pp. e64579-e64579.
• Chen, Y, Bui, A, Diesch, J et al 2013, 'A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling', Circulation Research, vol. 113, no. 3, pp. 252-265.
• Sheppard, K, Cullinane, C, Hannan, K et al. 2013, 'Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors', European Journal of Cancer, vol. 49, no. 18, pp. 3936-3944.
• George, A, Purdue, B, Gould, C et al 2013, 'A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation', Journal of Cell Science, vol. 126, no. 23, pp. 5377-5390.
• George, A, Hannan, R & Thomas, W 2013, 'Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches', The FEBS Journal, vol. 280, no. 21, pp. 5258-5268.
• Boglev, Y, Badrock, A, Trotter, A et al. 2013, 'Autophagy Induction Is a Tor- and Tp53-Independent Cell Survival Response in a Zebrafish Model of Disrupted Ribosome Biogenesis', PLoS Genetics, vol. 9, no. 2, pp. e1003279-e1003279.
• Bruhn, M, Pearson, R, Hannan, R et al 2013, 'AKT INDEPENDENT PI3 K SIGNALING IN CANCER EMERGING ROLE FOR SGK3', Cancer Management and Research, vol. 5, pp. 281-92.
• Hannan, K, Sanij, E, Rothblum, L et al. 2013, 'Dysregulation of RNA polymerase I transcription during disease', Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, vol. 1829, no. 3-4, pp. 342-360.
• Bywater, M, Pearson, R, McArthur, G et al 2013, 'Dysregulation of the basal RNA polymerase transcription apparatus in cancer', Nature Reviews Cancer, vol. 13, no. 5, pp. 299-314.
• Hannan, R, Drygin, D & Pearson, R 2013, 'Targeting RNA polymerase I transcription and the nucleolus for cancer therapy', Expert Opinion on Therapeutic Targets, vol. 17, no. 8, pp. 873-878.
• Wall, M, Poortinga, G, Stanley, K et al. 2013, 'The mTORC1 Inhibitor Everolimus Prevents and Treats E mu-Myc Lymphoma by Restoring Oncogene-Induced Senescence', Cancer Discovery, vol. 3, no. 1, pp. 82-95.
• Hein, N, Hannan, K, George, A et al. 2013, 'The nucleolus: An emerging target for cancer therapy', Trends in Molecular Medicine, vol. 19, no. 11, pp. 643-654.
• Devlin, J, Hannan, K, Ng, P et al. 2013, 'AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo', The FEBS Journal, vol. 280, no. 21, pp. 5307-5316.
• Shortt, J, Martin, B, Hannan, K et al. 2013, 'Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas', Blood, vol. 121, no. 15, pp. 2964-2974.
• George, A, Purdue, B, Gould, K et al 2012, 'A Functional SiRNA Screening Approach to Investigate the Mechanism Underlying GPCR-mediated EGFR Transactivation in Malignancy', European Journal of Cancer, vol. 48, no. 5, pp. S149-S149.
• Pakay, J, Diesch, J, Gilan, O et al 2012, 'A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells', Oncogene, vol. 31, no. 14, pp. 1817-1824.
• Bywater, M, Hannan, R, Poortinga, G et al 2012, 'Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53', Cancer Cell, vol. 22, no. 1, pp. 51-65.
• Quinn, L, Cranna, N, Lee, J et al 2012, 'Steroid hormones in Drosophila: how ecdysone coordinates developmental signalling with cell growth and division', in Hassan Abduljabbar (ed.), Steroids - Basic Science, InTech, Rijeka, Croatia, pp. 141-168.
• Hein, N, Sanij, E, Quin, J et al. 2012, 'The nucleolus and ribosomal genes in aging and senescence', in Tetsuji Nagata (ed.), Senescence, InTech, Rijeka, Croatia, pp. 171-203.
• Astle, M, Hannan, K, Ng, P et al. 2012, 'AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: Implications for targeting mTOR during malignancy', Oncogene, vol. 31, no. 15, pp. 1949-1962.
• Hannan, K, Sanij, E, Hein, N et al. 2011, 'Signaling to the Ribosome in Cancer-It Is More Than Just mTORC1', IUBMB Life, vol. 63, no. 2, pp. 79-85.
• Lee, R, House, C, Cristiano, B et al. 2011, 'Relative expression levels rather than specific activity plays the major role in determining in vivo AKT isoform substrate specificity', Enzyme Research, vol. 2011, no. 1.
• Jastrzebski, K, Hannan, K, House, C et al. 2011, 'A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth', Cellular Signalling, vol. 23, no. 8, pp. 1338-1347.
• Smith, N, Chan, H, Qian, H et al. 2011, 'Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy', Hypertension, vol. 57, no. 5, pp. 973-U217.
• Poortinga, G, Wall, M, Sanij, E et al 2011, 'C-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol i availability during granulocyte differentiation', Nucleic Acids Research, vol. 39, no. 8, pp. 3267-3281.
• Drygin, D, Lin, A, Bliesath, J et al 2011, 'Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth', Cancer Research, vol. 71, no. 4, pp. 1418-1430.
• Cranna, N, Mitchell, N, Hannan, R et al 2011, 'Hfp, the Drosophila homolog of the mammalian c-myc transcriptional-repressor and tumor suppressor FIR, inhibits dmyc transcription and cell growth', Fly (Landes Bioscience), vol. 5, no. 2, pp. 129-133.
• #equal contribution #Chan, J, #Hannan, K, Riddell, K et al 2011, 'AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer', Science Signaling, vol. 4, no. 188.
• Lin, J, Mitchell, et al *Quinn L.M. and Hannan R.D. (*co-senior authors) 2011, 'Drosophila ribosomal protein mutants control tissue growth non-autonomously via effects on the prothoracic gland and ecdysone', PLoS Genetics, vol. 7, no. 12, pp. 1-18.
• George, A, Thomas, W & Hannan, R 2010, 'The renin-angiotensin system and cancer: Old dog, new tricks', Nature Reviews Cancer, vol. 10, no. 11, pp. 745-759.
• Wong, L, McGhie, J, Sim, M et al 2010, 'ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells', Genome Research, vol. 20, no. 3, pp. 351-360.
• Mitchell, N, Johanson, T, Cranna, N et al. 2010, 'Hfp inhibits Drosophila myc transcription and cell growth in a TFIIH/Hay-dependent manner', Development, vol. 137, no. 17, pp. 2875-2884.
• Bruhn, M, Hannan, R, Pearson, R et al. 2010, 'Second AKT: The rise of SGK in cancer signalling', Growth Factors, vol. 28, no. 6, pp. 394-408.
• Wall, M, Poortinga, G, Hannan, K et al. 2008, 'Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation', Blood, vol. 112, no. 6, pp. 2305-2317.
• Sanij, E, Poortinga, G, Sharkey, K et al. 2008, 'UBF levels determine the number of active ribosomal RNA genes in mammals', Journal of Cell Biology, vol. 183, no. 7, pp. 1259-1274.
• Jastrzebski, K, Hannan, K, Tchoubrieva, E et al. 2007, 'Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function', Growth Factors, vol. 25, no. 4, pp. 209-226.
• Cristiano, B, Chan, J, Hannan, K et al. 2006, 'A specific role for AKT3 in the genesis of ovarian cancer through modulation of G2-M phase transition', Cancer Research, vol. 66, no. 24, pp. 11718-11725.
• Poortinga, G, Hannan, K, Snelling, H et al. 2004, 'MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation', The EMBO Journal, vol. 23, no. 16, pp. 3325-3335.
• Hannan, K, Brandenburger, Y, Jenkins, A et al. 2003, 'mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBF', Molecular and Cellular Biology, vol. 23, no. 23, pp. 8862-8877.
• Hannan, K, Hannan, R, Smith, S et al. 2000, 'Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1', Oncogene, vol. 19, no. 43, pp. 4988-4999.
• Hannan, K, Kennedy, B, Cavanaugh, A et al. 2000, 'RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest', Oncogene, vol. 19, no. 31, pp. 3487-3497.
• Hannan, K, Hannan, R & Rothblum, L 1998, 'Transcription by RNA polymerase I.', Frontiers in Bioscience, vol. 3, pp. d376-398.
• Hannan, R, Taylor, L, Cavanaugh, A et al. 1997, 'UBF and the regulation of ribosomal DNA transcription', in M Paule (ed.), Transcription of Ribosomal RNA genes by Eukaryotic RNA Polymerase I, Landes Bioscience, New York, pp. 221-232.

Projects and Grants

Grants information is drawn from ARIES. To add or update Projects or Grants information please contact your College Research Office.

• Ribosome biogenesis and disease (Primary Investigator)
• How novel ribosomal RNA gene repeat variants drive cellular function (Secondary Investigator)
• NHMRC Equipment Grant 2021: ACDT Equipment - Linked to ARIES ID 39296 (Primary Investigator)
• The nucleolar stress response at the centre of the malignant phenotype (Secondary Investigator)
• BioTek MultiFlo FX with AMX Module and Wash Module (see 37697) (Primary Investigator)
• Targeting cancer metabolism to reduce metastases (Secondary Investigator)
• TARGETING RNA POLYMERASE I TO TREAT CANCER (Primary Investigator)
• Harnessing the Nucleolar Surveillance Response to Treat Disease (Primary Investigator)
• Identifying therapeutics which can be repurposed for the treatment of Myelodysplastic Syndrome and other Bone Marrow Failure Disorders (Secondary Investigator)
• Determining how FUBP1 drives Oligodendroglioma to develop better treatments for primary brain cancer (Secondary Investigator)
• Novel Therapies for Osteosarcoma: RNA Pol I Inhibitors (Secondary Investigator)
• IntelliCyt iQue QMAX Refill Module (see 34173) (Primary Investigator)
• Mechanisms and targets of protein synthesis dysregulation in cancer (Secondary Investigator)
• How ribosomal protein loss affects cell fate (Primary Investigator)
• Therapeutic targeting of ribosome biogenesis in cancer and ribosomopathies (Primary Investigator)
• The ACRF Department of Cancer Biology and Therapeutics (Primary Investigator)
• Regulation of ribosomal gene chromatin during malignant transformation (Primary Investigator)
• Development of broad spectrum, non-genotoxic cancer treatments for acute myeloid leukaemias and multiple myeloma (Primary Investigator)
• Novel combination therapies targeting the ribosome to treat prostate cancer (PC) (Primary Investigator)
• The Australian Diamond-Blackfan Anaemia Program (ADBA) - including CRISPR and Therapeutic program (Primary Investigator)
• Senior Research Fellowship B (Primary Investigator)
• Oncogenic signaling and cancer therapy - External led (Secondary Investigator)
• Centenary Chair in Cancer Research (Primary Investigator)

Related websites

• https://www.petermac.org/research/programs/oncogenic-signalling-growth-control
  

  The Peter MacCallum Cancer Centre, Melbourne Australia where Professor Hannan maintains  a 0.2 EFT Position as Laboratory Head.